—
Enter label dose
Trial reference
From your label
Enter your label dose — the gauge updates instantly.
1000 mcg/day oral methylcobalamin for a year normalised B12 and improved nerve conduction in metformin-treated diabetic neuropathy; the Cochrane review found oral matches intramuscular for correcting levels. After labs, with clinician oversight.
Educational only — not medical advice. Disclaimer.
NIH DSLD market slice
Bulk CSV dump 16 January 2026 · label entries through 2025. Disclosed amounts only — proprietary blends without gram weights excluded.
Trial floors
Primary
Oral repletion (deficiency confirmed) · 1,000 mcg over 1 year · Benefit shown — 1000 mcg/day oral methylcobalamin for a year normalised B12 and improved nerve conduction in metformin-treated diabetic neuropathy; the Cochrane review found oral matches intramuscular for correcting levels. After labs, with clinician oversight.
Secondary
Typical multivitamin (not therapeutic) · 6–25 mcg — Illustrative floor only — not sufficient for metformin-associated deficiency repletion.
Label reading notes
- Serum B12 (± MMA) before high-dose repletion — labels cannot diagnose deficiency. A daily multivitamin (often 6–25 mcg) is not therapeutic repletion after confirmed deficiency.
- Repletion trials in metformin users used 1000 mcg/day oral cyanocobalamin or methylcobalamin. Cochrane data support high-dose oral against intramuscular for correcting levels; sublingual upsells are usually marketing at that dose.
- Check serving size on gummies and sprays — some split 1000 mcg across two pieces or list compound weight instead of micrograms of B12.
- After repletion, maintenance dose and duration are clinician decisions, especially with neuropathy, prior GI surgery, or persistent symptoms despite normal labs.
